14 March 2025 in Nature Chemical Biology
Engineering of nuclear condensates with chemically inducible gene switches is highly desired but challenging for precise and on-demand regulation of mammalian gene expression. Here, we harness the phase-separation capability of biomolecular condensates and describe a versatile strategy to chemically program ligand-dependent gene expression at various stages of interest. By engineering synthetic anchor proteins capable of tethering various genetically encoded condensate structures toward different cellular compartments or gene products of interest, inducible regulation of transcriptional and translational activities was achieved at different endogenous and episomal loci using the same sets of anchor proteins and synthetic solid-state condensates. Using such a holistic condensate-based strategy, we not only achieved regulation performances comparing favorably to state-of-the-art strategies described for CRISPR–Cas9 activity and transcriptional silencing but further showed that chemically inducible retention of mRNA molecules into engineered condensate structures within the nucleus can become a remarkably efficient alternative for translational regulation.
1 January 2026 in Science
Small molecule–regulated protein oligomerization provides a powerful mechanism for manipulating biological processes by controlling protein proximity with high temporal precision. However, such systems only rarely exist in nature and remain a substantial challenge for de novo design. In this work, we describe a computational method for designing protein homooligomers whose assembly is regulated by small-molecule ligands with matching symmetry. We designed protein homotrimers regulated by the Food and Drug Administration (FDA)–approved drug amantadine and further designed amantadine-responsive heterodimers and heterotrimers. Biophysical characterization confirmed their amantadine-dependent assembly, and their crystal structures closely matched the design models. We demonstrated their broad applicability in controlling protein localization, membraneless condensate formation, and gene expression. Our approach opens new avenues for designing small molecule–responsive proteins and expands the chemogenetic toolkit for manipulating complex biological processes.
9 April 2026 in Trends in Biotechnology
In this study, we describe a rationally designed light-inducible RNA-releasing protein (LIRP) capable of inhibiting mRNA translation in the dark while permitting gene expression upon exposure to blue or ambient light. This LIRP-dependent gene switch is compatible with various delivery routes of gene- and cell-based therapy, such as subcutaneous implantation of microencapsulated light-sensitive cells or expression in various light-accessible body sites using single adeno-associated virus (AAV) vectors. To exemplify a gene therapy approach that directly harnesses ambient light as a natural illumination source to induce therapeutic action, we show how intradermal delivery of AAV2 vectors carrying a LIRP-regulated gene switch controlling murine thymic stromal lymphopoietin expression was effective in enabling light-dependent prevention and treatment of diet-induced obesity. To describe another therapeutic scenario, we engineered AAV2 vectors for LIRP-dependent expression of Vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinal neovascular diseases. Upon intravitreal delivery into mice suffering from wet macular degeneration, VEGF inhibitors were constantly produced when animals were exposed to daylight, but therapeutic actions could be flexibly interrupted either by exposure to dark environments or by administration of a selective blue light filter at any point in time. When compared to conventional treatment strategies based on constitutive VEGF inhibition over the course of 3 months, we show that a regulated gene therapy approach through LIRP-dependent optogenetics was advantageous in maintaining a normal retina thickness. This work not only provides a valuable addition to the optogenetic toolbox but also offers a perspective to translate light-dependent gene switches toward therapeutic usage.
23 January 2024 in Research Square
Engineering nucleic condensates with chemically inducible gene switches is highly desired but challenging for precise and on-demand regulation of mammalian gene expression. Here, we harness the phase separation capability of biomolecular condensates and describe a versatile strategy to chemically program ligand-dependent gene expression at various stages of interest. By engineering synthetic anchor proteins capable of tethering various genetically encoded condensate structures towards different cellular compartments or gene products of interest, inducible regulation of transcriptional and translational activities was achieved at different endogenous and episomal loci using the same sets of anchor proteins and synthetic condensates. Using such a holistic condensates-based strategy, we not only achieved regulation performances compared favorable to state-of-the art strategies described for CRISPR/Cas9 activity and transcriptional silencing, but further show that chemically inducible retention of mRNA molecules into engineered condensate structures within the nucleus can become a remarkably efficient alternative for translational regulation. Taken together, this work describes a systematic, scalable and universal strategy to regulate mammalian gene expression with substantially reduced (re)engineering labor during gene switch design, and broadens the current toolkit for chemical and synthetic biology.